Canaloplasty: First day microhyphaema

Article

Potentially a predictive factor for surgical success.

In a prospective, non-randomized study, my colleagues and I evaluated predictive factors for success in canaloplasty.10 The study group included 47 primary open angle glaucoma (POAG) patients with a mean IOP before surgery of 26.8 mmHg ± 5.2 (SD). The mean followup time was 20.6 months ± 8.3 (SD). The mean IOP was 8.4 mmHg ± 4.2 (SD) 1 day after surgery and 12.7 mmHg ± 1.7 (SD) at 24 months.

In a post-hoc analysis, there was no difference between patients with microhyphaema, compared to those without microhyphaema in regard to age, preoperative IOP, glaucomatous damage, number of medications and even in regard to day 1 IOP. However, the lower the target IOP after surgery was defined, the greater the differences in the complete success rates were between the two groups. For instance, the complete success rate in the eyes with microhyphaema was 87% compared to 21% in non-microhyphaema eyes for a target IOP under 16 mmHg, whereas it was 97% versus 71% respectively, for a target IOP less than 21 mmHg. Of note, eyes without microhyphaema required more frequent and earlier laser goniopuncture than eyes with microhyphaema (p < 0.001).

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.